News 24.04.2024 Schlieren (Zurich), Switzerland, April 24, 2024 – Kuros Biosciences (“Kuros”), a leader in advanced bone healing technologies, today announced its financial performance for the first quarter of 2024. Direct sales of MagnetOs rose 155% in the first three months of 2024, to CHF 13.9 million from CHF 5.4 million, compared...
News 23.04.2024 Zürich, April 22, 2024 In a notable collaboration that underscores the power of innovation in drug discovery, SanaGen and InSphero, alongside the renowned Sanquin research institute, have been awarded a 1.3 million euro grant for the ambitious project NOCAAVAAT. The NOCAAVAAT project, which aims to develop a breakthrough gene therapy for severe Alpha-1 anti-Trypsin (AAT)...
News 17.04.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that all motions proposed by the Board of Directors at the Annual General meeting were...
News 17.04.2024 Schlieren (Zurich), Switzerland, April 17, 2024 – Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today. The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and the Consolidated Financial Statements for the year 2023 and took note of the Reports...
News 05.04.2024 Zurich, Switzerland - 04.04.2024 Neurimmune today announced that its collaboration partner Alexion, AstraZeneca’s Rare Disease group, initiated the Phase 3 DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 (formerly NI006) for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) (NCT06183931). ALXN2220 is an investigational human monoclonal antibody designed to deplete...